Our Story

InnoCare was started from a group highly motivated scientists with a single focus, to provide patients around the world with modern, innovative drugs in the battle against cancers and autoimmune diseases.

Founded in 2015, we have had many distinguished accomplishments, including the submission of our first NDA for Orelabrutinib, a highly selective BTK inhibitor.